Introduction {#S0001}
============

Recently, it is estimated that there will be 1,033,701 new gastric carcinoma (GC) cases and 782,685 GC-related deaths worldwide in 2018, ranking as the sixth most frequent malignancy and the second leading cause of cancer death.[@CIT0001] The Siewert II and III adenocarcinoma of esophagogastric junction (AEG) is considered as a subtype of GC. However, AEG has a quite extraordinary clinicopathological characteristic and may be very different to common GC. The etiology of AEG is unclear. It is one of the human complex diseases, which may be caused by genetic predisposition and environmental factors.

MicroRNAs (miRNAs) are a cohort of small non-coding RNA molecules, which contain about 22 nucleotides. It was found that miRNAs play important roles in RNA silencing and post-transcriptional regulation. MiRNAs take part in regulation of cell proliferation, differentiation, oncogenesis, apoptosis, and angiogenesis.[@CIT0002]--[@CIT0007] Alterations in the regulation of transcription may lead to the changes in miRNA expression in carcinogenesis.[@CIT0008] Stojanovic et al reported that miRNAs expression profiles may consider as useful biomarkers of diagnosis in GC.[@CIT0009]

Recently, a number of case--control studies were carried out to explore the relationship of miRNA-499 rs3746444 A\>G variants with risk of GC.[@CIT0010]--[@CIT0015] Some previous studies reported that miRNA-499 rs3746444 A\>G variants influenced the risk of GC and this polymorphism might be used as a potential biomarker for GC prediction.[@CIT0011],[@CIT0014] The miRNA-499 rs3746444 A\>G polymorphism was also associated with overall survival and progression-free survival among cases of neoadjuvant chemotherapy.[@CIT0016] A meta-analysis indicated that miRNA-499 rs3746444 variants were risk factors for overall cancer development.[@CIT0017],[@CIT0018] However, the correlation of miRNA-499 rs3746444 A\>G variants with the susceptibility of AEG remains unclear. To shed some light on this issue, 2740 participants were included and analyzed the association between miRNA-499 rs3746444 A\>G variants and the development of AEG.

Materials and methods {#S0002}
=====================

Subjects {#S0002-S2001}
--------

The present case--control study was performed by cooperation among Fujian Medical University Union Hospital, the Affiliated Cancer Hospital of Fujian Medical University and the Affiliated People's Hospital of Jiangsu University. Two hundred and eighty AEG patients were consecutively enrolled between January 2014 and May 2016 from two Affiliated Hospitals of Fujian Medical University mentioned earlier. Seven hundred and eighty-three AEG cases were recruited from the Affiliated People's Hospital of Jiangsu University from January 2008 to November 2016 consecutively. In this study, all AEG cases were diagnosed as Siewert type II by gastroscope and operation. All AEG cases were pathologically confirmed. And 1677 healthy subjects without any cancer history served as controls, age, and gender matched. Before collecting blood samples, a written informed consent was obtained from each participant. This investigation protocol met with the Declaration of Helsinki and was approved by the ethics committee of Jiangsu University (No. K-20170050-Y). They were inquired by a questionnaire and face-to-face interview. The following information was collected: age, sex, alcohol consumption, and smoking history. The information of lymph node status was obtained from medical records. The TMN stage was determined by American Joint Committee on Cancer (AJCC, 7th edition). The related risk factors and clinical data are summarized in [Table 1](#T0001){ref-type="table"}.Table 1Distribution of selected demographic variables and risk factors in AEG cases and controlsVariableAEG Cases (n=1063)Controls (n=1677)*P*^a^n%n%Age (years)64.19 (±8.63)63.91 (±10.22)0.451Age (years)0.165 \<6449446.4782549.19 ≥6456953.5385250.81Sex0.909 Male75971.40119471.20 Female30428.6048328.80Smoking status**\<0.001** Never77372.72132378.89 Ever29027.2835421.11Alcohol use**\<0.001** Never90885.42150789.86 Ever15514.5817010.14Lymph node status Positive62558.80 Negative43841.20TMN stage I/II30528.69 III/IV75871.31[^2][^3]

Selection of SNPs {#S0002-S2002}
-----------------

MiRNA-499 rs3746444 A\>G was selected according to some previous publications.[@CIT0014],[@CIT0017],[@CIT0019],[@CIT0020] The corresponding information of miRNA-499 rs3746444 A\>G SNP is presented in [Table 2](#T0002){ref-type="table"}.Table 2Primary information for miRNA-499 rs3746444 A\>G polymorphismGenotyped polymorphismmiR-499 rs3746444Chromosome20NCBI Build 3834990448Regionnc transcript variantMAF in our controls (n=1677)0.150*P*-value for HWE test in our controls0.500% Genotyping value99.05[^4]

DNA extraction and genotyping {#S0002-S2003}
-----------------------------

Blood was collected in EDTA test tube from 2740 participants. Details on blood draw, DNA extraction, and storage status were described in the previous study.[@CIT0021] Genotyping was conducted at ABI 3730XL sequencer using a custom-designed SNPscan^TM^ assay (Genesky Biotechologies Inc., Shanghai, China).[@CIT0022] For quality control, the obtained variants of miRNA-499 rs3746444 A\>G polymorphism were confirmed by genotyped in 4% randomly selected genomic DNA samples. And the results of the quality control were in accord with the first assays.

Statistical analysis {#S0002-S2004}
--------------------

Age among cases and controls was expressed as the mean±standard deviation (SD). Student's *t*-test was used to assess age difference between AEG patients and controls. Differences of the categorical variable (eg, age, gender, smoking, alcohol consumption, and the number of miR-499 rs3746444 A\>G genotypes) between AEG patients and controls were determined by using χ^2^-test. To calculate odds ratios (ORs) and their 95% confidence intervals (CIs), we used a multiple logistic regression model. In multivariate model, the confounding risk factors, including age (\<64, ≥64), gender (male, female), smoking (ever, never), and alcohol consumption (ever, never) were used to adjust the risk to AEG. We also carried out stratified analyses to explore the relationship of miRNA-499 rs3746444 A\>G polymorphism with AEG risk in different subgroups. In this study, the association of miRNA-499 rs3746444 A\>G polymorphism with lymph node status in AEG patients was also assessed by a multiple logistic regression model. An online program (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) was used to examine for deviation from Hardy--Weinberg equilibrium (HWE).[@CIT0023] Statistical analyses were conducted with SAS 9.4 (SAS Institute, Cary, North Carolina), and all *P*-values are two-sided. In the present study, *P*\<0.05 was considered as the level of significance. Power value (α=0.05) was calculated by the online Power and Sample Size Calculator software (<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>).[@CIT0024]

Results {#S0003}
=======

Baseline characteristics {#S0003-S2001}
------------------------

In total, 2740 age/gender-matched Chinese Han subjects (1063 AEG patients and 1677 non-cancer history controls) were included in this hospital-based case--control study to assess the correlation of miRNA-499 rs3746444 A\>G polymorphism with risk of AEG. Clinicopathological features and confounding factors are listed in [Table 1](#T0001){ref-type="table"}. There were no significant differences in age and gender (mean age of AEG patients vs controls: 64.19±8.63 years vs 63.91±10.22 years, *P*=0.451; number of cases vs controls (male/female): 759/304 vs 1194/483, *P*=0.909). There were statistically significant differences in smoking, alcohol consumption (smoking status of AEG patients vs controls (ever/never): 773/290 vs 1323/354, *P*\<0.001; alcohol consumption of cases vs controls (male/female): 908/155 vs 1507/170, *P*\<0.001). In AEG group, patients included 305 cases with stage I/II and 758 with stage Ⅲ/IV of the disease. Tumor stage was determined according to AJCC (7th edition). Among the 1063 AEG cases, 625 patients accompanied by lymph node metastasis. The frequencies of the miRNA-499 rs3746444 polymorphism in controls did not deviate from the HWE (*P*=0.500, [Table 2](#T0002){ref-type="table"}).

Association of miRNA-499 rs3746444 variants with AEG {#S0003-S2002}
----------------------------------------------------

Genotype frequency and percentage of the miRNA-499 rs3746444 A\>G polymorphism are summarized in [Table 3](#T0003){ref-type="table"}. We list the relationship between this SNP and AEG susceptibility in [Table 4](#T0004){ref-type="table"}. SNP miRNA-499 rs3746444 A\>G polymorphism had an increased susceptibility to AEG (AG vs AA: adjusted OR=1.29, 95% CI=1.08--1.53, *P*=0.005 and AG/GG vs AA: adjusted OR=1.30, 95% CI=1.10--1.54, *P*=0.002, [Table 4](#T0004){ref-type="table"}).Table 3The frequencies of miRNA-499 rs3746444 A\>G polymorphisms in AEG patients and controlsGenotypeOverall cases (n=1063)Stage I/II patients (n=305)Stage III/IV patients (n=758)Controls (n=1677)n%n%n%n%AA69566.8319966.7849666.85121472.52AG31129.909030.2022129.7841925.03GG343.2793.02253.37412.45AG+GG34533.179933.2224633.1546027.48AA+AG1,00696.7328996.9871796.63163397.55GG343.2793.02253.37412.45G allele37918.2210818.1227118.2650114.96 Table 4Association of miRNA-499 rs3746444 A\>G polymorphism with AEGGenotypeOverall patients (n=1063) vs controls (n=1677)Stage I/II patients (n=305) vs controls (n=1677)Stage III/IV patients (n=758) vs controls (n=1677)Crude OR(95%CI)*P*Adjusted OR^a^ (95%CI)*P*Crude OR(95%CI)*P*Adjusted OR^a^ (95%CI)*P*Crude OR(95%CI)*P*Adjusted OR^a^ (95%CI)*P*GA vs AA**1.30 (1.09--1.54)0.0031.29 (1.08--1.53)0.005**1.31 (1.00--1.72)0.0521.29 (0.98--1.70)0.068**1.29 (1.06--1.57)0.0101.28 (1.05--1.55)0.013**GG vs AA1.45 (0.91--2.30)0.1181.46 (0.92--2.33)0.1121.34 (0.64--2.80)0.4371.41 (0.67--2.96)0.3621.49 (0.90--2.48)0.1231.50 (0.90--2.50)0.118GA/GG vs AA**1.31 (1.11--1.55)0.0021.30 (1.10--1.54)0.0021.31 (1.01--1.71)0.043**1.30 (1.00--1.70)0.052**1.31 (1.09--1.58)0.0051.30 (1.08--1.57)0.006**GG vs GA/AA1.35 (0.85--2.14)0.2071.36 (0.86--2.16)0.1941.24 (0.60--2.58)0.5641.31 (0.63--2.75)0.4671.39 (0.84--2.30)0.2021.40 (0.84--2.33)0.192[^5]

Association of miRNA-499 rs3746444 A\>G polymorphism with AEG in different subgroups {#S0003-S2003}
------------------------------------------------------------------------------------

After adjustment by age, gender, smoking, and alcohol consumption, in stage III/IV patients, we also identified that miRNA-499 rs3746444 A\>G polymorphism increased the risk of AEG (AG vs AA: adjusted OR=1.28, 95% CI=1.05--1.55, *P*=0.013 and AG/GG vs AA: adjusted OR=1.30, 95% CI=1.08--1.57, *P*=0.006, [Table 4](#T0004){ref-type="table"}).

[Table 5](#T0005){ref-type="table"} summarizes the genotype frequencies of miRNA-499 rs3746444 A\>G polymorphism in different subgroups. After adjustment by confounding factors (age, gender, smoking, and alcohol consumption), we found that miRNA-499 rs3746444 A\>G polymorphism increased the risk of AEG in several subgroups (male subgroup: AG vs AA: adjusted OR=1.39, 95% CI=1.13--1.70, *P*=0.002 and AG/GG vs AA: adjusted OR=1.36, 95% CI=1.12--1.66, *P*=0.002; female subgroup: GG vs AA: adjusted OR=2.36, 95% CI=1.02--5.44, *P*=0.044 and GG vs AG/AA: adjusted OR=2.33, 95% CI=1.01--5.33, *P*=0.046; \<64 years subgroup: AG vs AA: adjusted OR=1.47, 95% CI=1.14--1.89, *P*=0.003 and AG/GG vs AA: adjusted OR=1.45, 95% CI=1.13--1.85, *P*=0.003; never smoking subgroup: AG vs AA: adjusted OR=1.40, 95% CI=1.15--1.72, *P*=0.001 and AG/GG vs AA: adjusted OR=1.41, 95% CI=1.16--1.72, *P*=0.001; and never drinking subgroup: AG vs AA: adjusted OR=1.33, 95% CI=1.11--1.61, *P*=0.003 and AG/GG vs AA: adjusted OR=1.33, 95% CI=1.11--1.60, *P*=0.002, [Table 5](#T0005){ref-type="table"}).Table 5Stratified analyses between miRNA-499 rs3746444 A\>G polymorphism and AEG risk by sex, age, smoking status, and alcohol consumptionVariablemiRNA-499 rs3746444 A\>G (case/control)^a^Adjusted OR^b^ (95% CI); *P*AAAGGGAAAGGGAG/GGGG vs (AG/AA)Sex Male492/867233/29320/311.00**1.39 (1.13--1.70);**\
***P*: 0.002**1.14 (0.64--2.04);\
*P*: 0.647**1.36 (1.12--1.66);**\
***P*: 0.002**1.04 (0.59--1.85);\
*P*: 0.886 Female203/34778/12614/101.001.05 (0.75--1.47);\
*P*: 0.761**2.36 (1.02--5.44);**\
***P*: 0.044**1.15 (0.84--1.58);\
*P*: 0.391**2.33 (1.01--5.33);**\
***P*: 0.046**Age \<64312/599157/20313/211.00**1.47 (1.14--1.89);**\
***P*: 0.003**1.24 (0.61--2.52);\
*P*: 0.560**1.45 (1.13--1.85);**\
***P*: 0.003**1.10 (0.54--2.24);\
*P*: 0.783 ≥64383/615154/21621/201.001.13 (0.89--1.45);\
*P*: 0.3141.67 (0.89--3.14);\
*P*: 0.1081.18 (0.93--1.49);\
*P*: 0.1681.62 (0.87--3.02);\
*P*: 0.132Smoking status Never499/970227/31627/351.00**1.40 (1.15--1.72);**\
***P*: 0.001**1.50 (0.90--2.51);\
*P*: 0.121**1.41 (1.16--1.72);**\
***P*: 0.001**1.37 (0.82--2.28);\
*P*: 0.230 Ever196/24484/1037/61.001.01 (0.71--1.43);\
*P*: 0.9681.38 (0.45--4.24);\
*P*: 0.5751.03 (0.73--1.45);\
*P*: 0.8741.38 (0.45--4.21);\
*P*: 0.576Alcohol consumption Never593/1,097266/37027/381.00**1.33 (1.11--1.61);**\
***P*: 0.003**1.32 (0.80--2.19);\
*P*: 0.278**1.33 (1.11--1.60);**\
***P*: 0.002**1.22 (0.74--2.02);\
*P*: 0.437 Ever102/11745/497/31.000.98 (0.60--1.63);\
*P*: 0.9493.60 (0.84--15.54);\
*P*: 0.0861.11 (0.68--1.79);\
*P*: 0.6873.62 (0.85--15.50);\
*P*: 0.083[^6]

Power of this case--control study {#S0003-S2004}
---------------------------------

For miRNA-499 rs3746444 A\>G polymorphism, the power value (α=0.05) was 0.817 in AG vs AA genetic model and 0.882 in AG/GG vs AA genetic model among overall comparison, 0.729 in AG vs AA genetic model and 0.805 in AG/GG vs AA genetic model in III/IV patients subgroup, 0.883 in AG vs AA genetic model and 0.830 in AG/GG vs AA genetic model among male subgroup, 0.649 in GG vs AA genetic model and 0.536 in GG vs AG/AA genetic model among female subgroup, 0.854 in AG vs AA genetic model and 0.851 in AG/GG vs AA genetic model among \<64 years subgroup, 0.902 in AG vs AA genetic model and 0.932 in AG/GG vs AA genetic model among never smoking subgroup, and 0.847 in AG vs AA genetic model and 0.871 in AG/GG vs AA genetic model among never drinking subgroup. The results of power calculation confirmed that miRNA-499 rs3746444 A\>G polymorphism increased the risk of AEG in overall comparison, male, \<64 years, never smoking and never drinking subgroups.

Association of miRNA-499 rs3746444 A\>G polymorphism with lymph node status in AEG patients {#S0003-S2005}
-------------------------------------------------------------------------------------------

In total, 1063 AEG patients were included in the present study to assess the relationship of the miRNA-499 rs3746444 A\>G polymorphism with lymph node status of AEG. Among these AEG cases, 625 patients accompanied by positive lymph node. As listed in [Table 6](#T0006){ref-type="table"}, the distribution of miRNA-499 rs3746444 A\>G variants was no significant difference among different variants.Table 6Logistic regression analyses of association between miRNA-499 rs3746444 A\>G polymorphism and lymph node status in AEG patientsGenotypePositive (n=625)Negative (n=438)Crude OR (95%CI)*P*Adjusted OR^a^\
(95%CI)*P*n%n%miRNA-499 rs3746444 A \> GAA41868.1927764.871.001.00AG17428.3813732.080.84(0.64--1.10)0.2120.83(0.63--1.09)0.180GG213.43133.041.07(0.53--2.17)0.8511.05(0.52--2.14)0.891AG+GG19531.8115035.130.86(0.66--1.12)0.2640.85(0.65--1.11)0.224AA+AG59296.5741496.961.001.00GG213.43133.041.13(0.56--2.28)0.7341.11(0.55--2.25)0.768G allele21617.6216319.09[^7]

Discussion {#S0004}
==========

Accumulating evidence suggests a vital role for heredity in determining potential risk for malignancy. Yang et al recently performed a meta-analysis and identified the relationship between miRNA-499 rs3746444 A\>G variants and risk to overall cancer was significant involving 23,762 cases and 28,694 controls.[@CIT0018] In addition, this study reported that miRNA-499 rs3746444 A\>G variants also have been implicated in the risk of digestive system cancer. To the best of our knowledge, the current study is the first case--control study to explore the correlation of miRNA-499 rs3746444 A\>G polymorphism with the susceptibility of AEG.

MiRNA-499 is a common miRNA which was implicated in posttranscriptional regulatory.[@CIT0025] A previous study reported that miRNA-499 might facilitate the metastasis and cellular invasion of colorectal cancer by targeting PDCD4 and FOXO4.[@CIT0026] Thus, miRNA-499 might be considered as a useful therapeutic target for patients with colorectal cancer. Li et al reported that miRNA-499-3p have been identified in GC tissues.[@CIT0027] These findings indicated that miRNAs may contribute to the development of human GC. Recently, several case--control studies identified that miRNA-499 rs3746444 A\>G polymorphism might alter the risk of GC.[@CIT0011],[@CIT0014] Additionally, Tahara et al reported that the miRNA-499 rs3746444 G allele carrier was associated with a poorer prognosis in advanced GC performing chemotherapy.[@CIT0016] However, some meta-analysis have reported negative signals of miRNA-499 rs3746444 A\>G polymorphism with the risk of GC.[@CIT0018],[@CIT0020],[@CIT0028],[@CIT0029] The possible interpretation for the lack of association could be the sufficient sample size in previous study. In this case--control study, we established that the relationship between miRNA-499 rs3746444 A\>G variants and susceptibility to AEG was significant in overall comparison. In the subsequent stratified analyses, as summarized in [Table 5](#T0005){ref-type="table"}, observation of this study also showed that miRNA-499 rs3746444 A\>G polymorphism might increase the risk of AEG in male, \<64 years, never smoking, and never drinking subgroups. Our results for the association between miRNA-499 rs3746444 A\>G variants and AEG risk are based on related large sample sizes, which were analogous to the previous studies in Asians.[@CIT0018],[@CIT0020],[@CIT0028],[@CIT0030] However, our findings might be deciphered with very caution. In the future, further case--control studies with larger sample sizes and rigorous matching criteria considering more gene-environment factors are needed to explore the potential relationships.

Several merits and limitations should be acknowledged when explaining these observed results. Merits of this case--control study including its large sample size and the matching confounding factors that it was enrolled to analyze the relationship between miRNA-499 rs3746444 A\>G variants in relation to susceptibility of AEG. Concerns relate to certain potential selections and risk factors. The participants among controls enrolled from two local hospitals, which might lead to some possible biases. If included controls were more likely to possess some benign diseases than those who did not participate in a physical examination, this could have led to a bias of the correlation we observed. Finally, obesity and overweight are an established cancer risk factor. AEG is regarded as an obesity-/overweight-related malignancy.[@CIT0031]--[@CIT0033] However, for lack of the body mass index (BMI) data, we did not match this confounding factor. If this bias existing in our study, then the increased susceptibility that we have observed may be an overestimate of the potential risk effects of miRNA-499 rs3746444 A\>G polymorphism for AEG.

In summary, to our knowledge, this is the first case--control focusing on the possible correlation between miRNA-499 rs3746444 A\>G polymorphism and risk of AEG. The significant association of AEG susceptibility with miRNA-499 rs3746444 A\>G polymorphism observed suggests additional support for the vital role of miRNA in the development of AEG. In the future, further exploration of this genetic factor in relation to AEG susceptibility is needed.
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[^2]: **Notes:** ^a^Two-sided *χ*^2^ test and Student *t*-test.

[^3]: **Abbreviation:** TMN, tumor node metastasis.

[^4]: **Abbreviations:** MAF, minor allele frequency; HWE, hardy--weinberg equilibrium.

[^5]: **Notes:** ^a^Adjusted for age, sex, smoking status, and alcohol use in a logistic regression model. Bold values are statistically significant (*P*\<0.05).

[^6]: **Notes:** ^a^For miRNA-499 rs3746444 A\>G, the genotyping was successful in 1040 (97.84%) AEG cases, and 1674 (99.82%) non-cancer controls; ^b^Adjusted for multiple comparisons \[age, sex, smoking status, and alcohol consumption (besides stratified factors accordingly)\] in a logistic regression model; Bold values are statistically significant (*P*\<0.05).

[^7]: **Note:** ^a^Adjusted for age, sex, alcohol use and smoking status.
